Search

Kura Oncology Inc

Chiusa

SettoreSettore sanitario

11.74 -0.59

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.2

Massimo

12.19

Metriche Chiave

By Trading Economics

Entrata

5M

-68M

Vendite

2.6M

21M

EPS

-0.77

Margine di Profitto

-327.331

Dipendenti

260

EBITDA

7M

-66M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+136.26% upside

Dividendi

By Acuity

Utili prossimi

3 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

154M

1B

Apertura precedente

12.33

Chiusura precedente

11.74

Notizie sul Sentiment di mercato

By Acuity

61%

39%

276 / 339 Classifica in Healthcare

Kura Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2026, 20:08 UTC

Social Media

Kura Oncology Inc shares are advancing today, supported by increased retail commentary, despite pulling back from a session high earlier in the session.

16 set 2026, 20:10 UTC

Kura Oncology Inc shares fell sharply after an early spike, closing significantly below its 20-day moving average and near the lower end of its one-month range.

15 set 2026, 22:02 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from a low to a notable high during the session. No specific news was identified.

14 set 2026, 20:13 UTC

Kura Oncology Inc shares are higher in after-market hours, though no specific news was identified. The price remains below its 20-day moving average.

10 set 2026, 20:03 UTC

Social Media

Kura Oncology Inc shares are lower, continuing a three-day decline despite increasing sales and the approval of its menin inhibitor, KOMZIFTI.

9 set 2026, 22:41 UTC

Kura Oncology Inc shares are rising in after-market trading, reflecting positive momentum in the biotechnology sector despite earlier session declines.

8 set 2026, 20:02 UTC

News
Social Media

Kura Oncology Inc shares are lower today, influenced by declines in the Biotechnology sector despite the appointment of a new Chief Financial Officer.

3 set 2026, 19:47 UTC

Kura Oncology Inc shares are lower today, with no specific news driving the decline. Earlier, the stock rebounded from a session high.

2 set 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting strength amid weaker-than-expected job growth reported by ADP.

28 ago 2026, 20:08 UTC

Kura Oncology Inc shares are lower today, reflecting broader market trends and rising U.S. Treasury yields amid concerns over inflation and monetary policy.

27 ago 2026, 23:46 UTC

Kura Oncology Inc shares are higher in after-market hours, rebounding from earlier declines and staying above recent moving averages. No specific news was identified.

26 ago 2026, 23:41 UTC

Kura Oncology Inc shares are higher in after-market trading, supported by positive market sentiment despite no specific company news.

25 ago 2026, 23:06 UTC

News

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

24 ago 2026, 23:31 UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

21 ago 2026, 22:56 UTC

Kura Oncology shares declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above the 20-day moving average.

20 ago 2026, 23:16 UTC

Kura Oncology Inc shares are higher in after-market trading, despite no specific news to explain the move. The stock remains above its 20-day moving average.

19 ago 2026, 19:21 UTC

Social Media

Kura Oncology Inc shares are higher, supported by positive biotechnology sentiment and social media discussions about a recent swing position at $12.57.

18 ago 2026, 23:06 UTC

Kura Oncology shares are higher in after-market trading, aligning with broader market trends amid rising sovereign bond yields and inflation concerns.

17 ago 2026, 22:51 UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

14 ago 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

13 ago 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

12 ago 2026, 23:01 UTC

News
Social Media

Kura Oncology reported second-quarter revenue of $20.87 million, driven by a 57% increase in net product revenue for KOMZIFTI, shares higher in after-market hours.

10 ago 2026, 19:43 UTC

Event
News

Kura Oncology Inc shares rise as the company highlights ziftomenib's preclinical development in a *Blood* publication, enhancing its positioning in acute myeloid leukemia treatment.

7 ago 2026, 23:36 UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6 ago 2026, 21:02 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

5 ago 2026, 19:26 UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

4 ago 2026, 19:36 UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

3 ago 2026, 23:01 UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

31 lug 2026, 21:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

30 lug 2026, 19:49 UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

Confronto tra pari

Modifica del prezzo

Kura Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

136.26% in crescita

Previsioni per 12 mesi

Media 26.461 USD  136.26%

Alto 40 USD

Basso 12.15 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Kura Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

10

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

276 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.